Medvi vs Direct Meds: Medication Options and Eligibility Compared

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Full head-to-head: PlexusDx vs MEDVi →

What follows is an independent editorial comparison. PlexusDx holds no commercial relationship with Medvi or Direct Meds, and nothing here is an affiliate placement or paid endorsement.

People searching "Medvi vs Direct Meds" are usually asking a practical question: which program can actually put a GLP-1 medication in my hands, and am I eligible for it? This review keeps the focus on the medication side — how each service dispenses, who qualifies, and what the prescription does and does not settle. Both are among dozens of telehealth options operating in the weight-management space as of April 2026.

How each program dispenses medication

Medvi (Medvi Wellness) runs on a telehealth-plus-compounded-pharmacy structure: a virtual clinical evaluation, a provider-issued prescription, and dispensing of either brand-name FDA-approved GLP-1 therapy or compounded semaglutide and tirzepatide through licensed 503A compounding pathways. Its current program specifics are posted on Medvi's official website.

Direct Meds follows the same broad blueprint — telehealth intake feeding a compounded-pharmacy fulfillment channel. The exact medication menu, refill cadence, and fees shift over time, so the current terms on Direct Meds's own site are the only reliable source at the moment you read this.

Eligibility and the intake gate

In both programs, medication access begins with an online health questionnaire and a clinician review rather than a prescription you can simply add to a cart. Eligibility typically turns on the information you provide about weight history, medical conditions, and current medications. Neither service can hand out a GLP-1 without that provider sign-off, and neither guarantees approval before intake is complete.

The compounded-versus-brand question

The single largest medication difference in this category is dispensing pathway: FDA-approved branded product versus a compounded preparation of the same active molecule. That distinction affects sourcing, labeling, and cost, but it does not change the underlying pharmacology. A program is defined by which molecule it prescribes and how it is prepared — not by the logo on the portal.

Evidence behind the molecules

Whichever brand dispenses them, the compounds themselves carry a substantial trial record. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide act on appetite regulation, satiety signaling, and gastric emptying. The STEP program (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024) anchor the evidence base; effect sizes track the compound and dose, not the storefront.

The genetic layer both programs skip

Neither intake form asks about the genetics that set your metabolic starting line. Variants in FTO (fat-mass and obesity-associated), GLP1R (the receptor every GLP-1 compound binds), MC4R (a satiety and energy-balance hub), and TCF7L2 (tied to glucose handling and GLP-1 secretion) describe the terrain a clinician is prescribing into. These are pathway-level markers: they do not predict how you will respond to any single drug, but they do add context a bare prescription cannot. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including those four genes, so you walk into the conversation informed rather than guessing.

Where PlexusDx fits

PlexusDx dispenses semaglutide and tirzepatide through its own Weight Management Protocols — offered as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The difference is the upstream genetic read that pairs with the protocol, a "test before you invest" step most telehealth intakes leave out.

Not affiliated: PlexusDx has no commercial ties to Medvi or Direct Meds and did not receive compensation for this comparison.

Related reading on PlexusDx: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone.

Disclaimer: This article is educational. PlexusDx is not affiliated with Medvi or Direct Meds and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

Do Medvi and Direct Meds prescribe the same medications?

Both can prescribe GLP-1 receptor agonists through telehealth, and both may offer compounded semaglutide or tirzepatide. The available doses, formats, and any brand-name options differ by program and change over time, so confirm the current medication menu on each brand's own site before deciding.

Who is eligible for GLP-1 medication through these programs?

Eligibility is decided by a clinician after you complete an online health intake covering weight history, conditions, and current medications. Neither Medvi nor Direct Meds guarantees approval in advance, and neither dispenses a GLP-1 without that provider review being finished first.

Does the Precision Peptide Genetic Test tell me which medication to take?

No. It does not predict response to any specific compound or program. It maps pathway-level variants in FTO and MC4R, and TCF7L2 that describe your baseline GLP-1 biology — context that applies across every program, which you then discuss with a provider.

How does PlexusDx handle medication differently?

PlexusDx dispenses semaglutide and tirzepatide through its Weight Management Protocols and pairs them with an upstream genetic read. That pathway-level context on FTO, MC4R is the piece most telehealth intakes, including Medvi and Direct Meds, do not provide.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education